## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Principal Investigator, and the following team members: Computational Biologist, Medicinal Chemist, Machine Learning Specialist, Scientific Critic.

Here is context for this meeting:

[begin context 1]

You have access to Emerald Cloud Labs (ECL), a cloud lab provider that can run automated biology experiments. The full list of experiments and unit operations available at ECL are below. Please note that ECL currently cannot work with cell cultures and cannot synthesize small molecule drugs.

[end context 1]

[begin context 2]

Running Experiments

Collection of functions used to remotely conduct experiments in an ECL facility.

Liquid Transfers

ExperimentSamplePreparation -- Performs a list of basic operations for combining and preparing both liquid and solid samples in series.

ExperimentSerialDilute -- Performs a series of dilutions iteratively by mixing samples with diluents and transferring to another container of the diluent.

ExperimentAcousticLiquidHandling -- Transfers liquid samples with sound waves in nanoliter increments.

ExperimentAliquot -- Generates a series new samples by drawing from a source sample and optionally diluting them in a new buffer.

ExperimentTransfer -- Moves an amount of sample from a specified source to a specified destination vessel.

Solid Transfers

ExperimentTransfer -- Moves an amount of sample from a specified source to a specified destination vessel.

Organic Synthesis

ExperimentDNASynthesis -- Performs solid-phase deoxyribonucleic acid oligonucleotide synthesis of the given sequence or set of sequences using phosphoramidite chemistry.

ExperimentRNASynthesis -- Performs solid-phase ribonucleic acid oligonucleotide synthesis of the given sequence or set of sequences using phosphoramidite chemistry.

ExperimentPNASynthesis -- Performs solid-phase peptide synthesis of a given Peptide Nucleic Acid (PNA) sequencer set of sequences using Boc or Fmoc strategies.

ExperimentPCR -- Amplifies a target sequence from a small quantity of template nucleic acid samples using oligonucleotide primers complementary to the two ends of the target sequence.

ExperimentPeptideSynthesis -- Performs classical solution phase synthesis of amino acids.

ExperimentBioconjugation -- Covalently binding the specified samples through chemical crosslinking creates a sample composed of new specified identity models.

Separations

ExperimentTotalProteinDetection -- Measures total protein amount and labeling percentage using capillary electrophoresis.

ExperimentSolidPhaseExtraction -- Performs Solid Phase Extraction (SPE) to purify analyte molecules in the given samples by adsorbing analytes to a solid-phase resin, washing the resin with was buffer to remove impurities, and then eluting the analyte from the solid phase using an elution buffer.

ExperimentHPLC -- Performs High Pressure Liquid Chromatography (HPLC) to separate analyte molecules in the given samples on the basis of their relative affinity to a mobile phase and a solid phase by flowing mobile phase through columns at high pressures.

ExperimentSupercriticalFluidChromatography -- Performs Supercritical Fluid Chromatography (SFC) to separate analyte molecules in the given samples on the basis of their relative affinity to a solid phase by flowing a pressured carbon dioxide stream through columns at high pressures.

ExperimentFPLC -- Performs Fast Protein Liquid Chromatography (FPLC) to separate analyte molecules in the given samples on the basis of their relative affinity to a mobile phase and a solid phase by flowing mobile phase through semi-disposable columns at moderate pressures.

ExperimentAgaroseGelElectrophoresis -- Performs agarose gel electrophoresis to separate analyte molecules in a given sample on the basis of their electrophoretic mobility though an agarose gel.

ExperimentPAGE -- Performs Polyacrylamide Gel Electrophoresis (PAGE) to separate analyte molecules in a given sample on the basis of their electrophoretic mobility though a polyacrylamide slab gel.

ExperimentWestern -- Performs a capillary-based experiment analogous to the traditional Western blot to detect the presence of a specific protein in a given sample.

ExperimentCapillaryGelElectrophoresisSDS -- Performs a capillary gel electrophoresis-SDS (CGE-SDS) on protein samples to separate them by their molecular weight.

ExperimentIonChromatography -- Performs liquid chromatography to separate ionic species based on their interaction with a resin.

ExperimentFlashChromatography -- Performs rapid separation to purify chemical mixtures based on their polarity differences with the aid of air pressure.

ExperimentGCMS -- Performs gas chromatography by vaporizing volatilizable analytes in a sample and separating the gas-phase mixture via interaction with the stationary phase in the capillary column followed by injection of the separated analytes into a single quadrupole mass spectrometer to quantify the generated mass fragments by mass-to-charge ratio.

ExperimentLCMS -- Performs liquid chromatography (LC) to separate analyte molecules in the given sample, then ionizes each separated fraction to measure the mass-to-charge ratio of the molecules (MS).

ExperimentCrossFlowFiltration -- Performs filtration perpendicular to a filter.

ExperimentLiquidLiquidExtraction -- Separate the aqueous and organic phases of a given sample via pipette or phase separator, in order to isolate a target analyte that is more concentrated in either the aqueous or organic phase.

ExperimentDialysis -- Performs separation to remove small unwanted compounds by diffusion through a semipermeable membrane.

ExperimentCapillaryIsoelectricFocusing -- Performs capillary Isoelectric Focusing (cIEF) to separate proteins based on their isoelectric point or charge.

ExperimentGasChromatography -- Performs separation of volatile analytes in gas-phase based on their interaction with the solid/liquid stationary phase.

Spectroscopy Experiments

ExperimentNMR -- Measures the Nuclear Magnetic Resonance (NMR) of the given sample in one dimension in order to identify and characterize its chemical structure.

ExperimentNMR2D -- Measures the two-dimensional Nuclear Magnetic Resonance (NMR) spectra of the given sample by correlating many one-dimensional NMR signals in order to identify and characterize its chemical structure.

ExperimentAbsorbanceIntensity -- Measures Ultraviolet-Visible (UV-Vis) light absorbance of the given samples at a specific wavelength.

ExperimentAbsorbanceSpectroscopy -- Measures Ultraviolet-Visible (UV-Vis) light absorbance of the given samples at a range of wavelengths.

ExperimentAbsorbanceKinetics -- Measures Ultraviolet-Visible (UV-Vis) light absorbance of the given samples at a range of wavelengths over time.

ExperimentIRSpectroscopy -- Measures Infrared (IR) light absorbance of the given samples at a range of wavelengths.

ExperimentDynamicLightScattering -- Measures scattered light intensity by moving particles in a sample to assess the size, polydispersity, thermal stability and colloidal stability of particles in the sample.

ExperimentFluorescenceIntensity -- Excites the provided samples at given wavelength and records a measurement of fluorescence signal at an emission wavelength.

ExperimentFluorescenceSpectroscopy -- Excites the provided samples at range of given wavelengths and records a measurement of fluorescence signal at range of emission wavelengths.

ExperimentFluorescenceKinetics -- Excites the provided samples at given wavelength and monitors evolution of fluorescence signal at an emission wavelength over time.

ExperimentFluorescencePolarization -- Performs Fluorescence Polarization (FP), which assesses the fraction of sample bound to receptor by measuring the molecular rotation of a fluorophore.

ExperimentFluorescencePolarizationKinetics -- Performs Fluorescence Polarization (FP) kinetics, assesses the fraction of sample bound to receptor by measuring the molecular rotation of a fluorophore over time.

ExperimentLuminescenceIntensity -- Measures the intensity of light produced by a samples undergoing chemical or biochemical reaction at a specific wavelength.

ExperimentLuminescenceSpectroscopy -- Measures the intensity of light produced by a samples undergoing chemical or biochemical reaction at a range of wavelengths.

ExperimentLuminescenceKinetics -- Measures the intensity of light produced by a samples undergoing chemical or biochemical reaction at a range of wavelengths over time.

ExperimentNephelometry -- Measures the intensity of scattered light upon passing through a solution container suspended particles to characterize the amount of particles.

ExperimentNephelometryKinetics -- Measures the change in the intensity of light scattered by a sample over time that contains insoluble suspended particles.

ExperimentCircularDichroism -- Measures the differential absorption of specified samples' left and right circularly polarized light.

ExperimentThermalShift -- Measures changes in fluorescence emission of extrinsic fluorescent dyes or intrinsic molecular fluorescence to monitor conformational changes of nucleic acids or proteins across a temperature gradient.

ExperimentRamanSpectroscopy -- Measures the intensity inelastic scattering of photons as the result of molecular vibrations interacting with monochromatic laser light.

Mass Spectrometry

ExperimentMassSpectrometry -- Ionizes the given samples in order to measure the mass-to-charge ratio of the molecules in the samples.

ExperimentGCMS -- Performs gas chromatography by vaporizing volatilizable analytes in a sample and separating the gas-phase mixture via interaction with the stationary phase in the capillary column followed by injection of the separated analytes into a single quadrupole mass spectrometer to quantify the generated mass fragments by mass-to-charge ratio.

ExperimentLCMS -- Performs liquid chromatography (LC) to separate analyte molecules in the given sample, then ionizes each separated fraction to measure the mass-to-charge ratio of the molecules (MS).

ExperimentSupercriticalFluidChromatography -- Performs Supercritical Fluid Chromatography (SFC) to separate analyte molecules in the given samples on the basis of their relative affinity to a solid phase by flowing a pressured carbon dioxide stream through columns at high pressures. The output of this separation is then ionized in order to measure the mass-to-charge ratio of the molecules in the samples.

ExperimentICPMS -- Performs Inductively Coupled Plasma Mass Spectrometry (ICP-MS) experiment to analyze the element or isotope composition and concentrations of given samples.

Bioassays

ExperimentAlphaScreen -- Performs an ALPHA screen experiment with the given samples.

ExperimentTotalProteinQuantification -- Performs an absorbance- or fluorescence-based assay to determine the total protein concentration of given input samples.

ExperimentqPCR -- Performs a quantitative polymerase chain reaction (qPCR) which uses a thermocycler to amplify a target sequence (or sequences if multiplexing) from the sample using a primer set, quantifying the amount of DNA or RNA throughout the experiment using a fluorescent intercalating dye or fluorescently labeled probe.

ExperimentBioLayerInterferometry -- Quantifies the magnitude and kinetics of an interaction between a surface immobilized species and a solution phase analyte sample.

ExperimentWestern -- Performs a capillary-based experiment analogous to the traditional Western blot to detect the presence of a specific protein in a given sample.

ExperimentUVMelting -- Performs Ultraviolet-Visible (UV-Vis) light absorbance melting curve analysis of given samples.

ExperimentCapillaryELISA -- Performs capillary Enzyme-Linked Immunosorbent Assay (ELISA) experiment on the provided Samples for the detection of certain analytes.

ExperimentDifferentialScanningCalorimetry -- Performs capillary differential scanning calorimetry (DSC) by measuring the amount of energy required to heat a given sample with respect to a reference.

ExperimentELISA -- Performs a quantitative characterization of the specific antigen concentration in samples.

ExperimentDNASequencing -- Identifies the order of nucleotides in a strand of DNA.

Crystallography

ExperimentGrowCrystal -- Prepares crystals in crystallization plate and monitors the growth of crystals using visible light, ultraviolet light and cross polarized light.

ExperimentPowderXRD -- Measures the diffraction of x-ray radiation on given powder samples.

Sample Preparation

ExperimentDilute -- Adds a specified amount of solvent to specified samples.

ExperimentSamplePreparation -- Performs a list of basic operations for combining and preparing both liquid and solid samples in series.

ExperimentAliquot -- Generates a series new samples by drawing from a source sample and optionally diluting them in a new buffer.

ExperimentIncubate -- Heats and/or mixes the provided samples for a given amount of time at a given temperature, allowing for a follow up annealing time.

ExperimentMix -- Mixes and/or heats the provided samples for a given amount of time at a given rate and temperature.

ExperimentTransfer -- Moves an amount of sample from a specified source to a specified destination vessel.

ExperimentCentrifuge -- Spins down the provided samples for a given amount of time at a provided force or spin rate.

ExperimentDegas -- Performs a degassing procedure on the given samples using a specified technique.

ExperimentFilter -- Passes the provided samples through a given physical filter using a set of optional different methods.

ExperimentStockSolution -- Given a recipe containing a list of components and their amounts or concentrations, combines the components, prepares, and conditions the mixture to generate a stock solution sample.

ExperimentAutoclave -- Subjects the provided samples or containers to extreme heat and pressure in order to sterilize.

ExperimentEvaporate -- Evaporates solvent from a provided sample under high vacuum at a given temperature with centrifugation to prevent bumping.

ExperimentLyophilize -- Removes solvents from the provided samples via controlled freezing and sublimation under high vacuum.

ExperimentPellet -- Precipitates solids that are present in a solution, optionally aspirates off the supernatant, and resuspends the resulting pellet.

ExperimentFillToVolume -- Adds sample to the a container until its volume reaches the desired value.

ExperimentAcousticLiquidHandling -- Transfers liquid samples with sound waves in nanoliter increments.

ExperimentAdjustpH -- Adds acid or base titrant to change the pH of the given sample to the desired value.'

ExperimentResuspend -- Dissolve the specified solid samples with some amount of solvent.

ExperimentMagneticBeadSeparation -- Isolates targets from specified sample via magnetic bead separation, which uses a magnetic field to separate superparamagnetic particles from suspensions.

ExperimentMicrowaveDigestion -- Breaks down complex samples via microwave heating and acid/oxidizing agent to fully solubilize sample for subsequent operations, especially ICP-MS.

ExperimentSerialDilute -- Performs a series of dilutions iteratively by mixing samples with diluents and transferring to another container of the diluent.

ExperimentFlashFreeze -- Performs freezing of specified sample objects through immersion of the sample containers in liquid nitrogen.

ExperimentDesiccate -- Dries out solid substances by absorbing water molecules from the samples through exposing them to a chemical desiccant in a bell jar desiccator under vacuum or non-vacuum conditions.

ExperimentGrind -- Employs mechanical actions to break particles of solid samples into smaller powder particles, using a grinding apparatus

Property Measurement

ExperimentCountLiquidParticles -- Measures the number of suspended particles in a liquid colloid or very fine suspension sample.

ExperimentCoulterCount -- Measures the number and size distribution of suspended particles (typically cells) in a liquid colloid or very fine suspension sample.

ExperimentMeasureOsmolality -- Measures the concentration of osmotically active species in a solution.

ExperimentMeasureConductivity -- Measures the electrical conductivity of a sample by immersion of a conductivity probe into the solution.

ExperimentMeasureContactAngle -- Measures the contact angle of a fiber sample with a wetting liquid using a force tensiometer.

ExperimentMeasureDensity -- Measures the density of the given samples using a fixed volume weight measurement or a density meter.

ExperimentMeasureDissolvedOxygen -- Measures the partial pressure of oxygen in a sample by applying a constant voltage in a probe confined by an oxygen permeable membrane to detect oxygen reduction as an electrical signal.

ExperimentMeasurepH -- Measures the pH of the given sample using electrical potential sensors.

ExperimentMeasureWeight -- Measures the weight of the given samples using an appropriately sized balance.

ExperimentMeasureVolume -- Measures the volume of the given samples using ultrasonic measurement of liquid surface distance and prior parametrization of the surface distance to volume in the samples container to determine sample volumes.

ExperimentMeasureCount -- Measures the number of tablets in a given tablet sample by determining the average weight of the tablets in the sample and the total mass of the given tablet sample.

ExperimentImageSample -- Records an image of the given sample either from above or side on for larger transparent vessels.

ExperimentMeasureSurfaceTension -- Determines the surface tension of a sample by measuring the forces exerted on a small diameter rod as it is withdrawn from a sample.

ExperimentMeasureRefractiveIndex -- Measures the Refractive Index (RI) of the given sample with refractometer.

ExperimentCyclicVoltammetry -- Characterizes the reduction and oxidation processes of the given sample using Cyclic Voltammetry (CV).

ExperimentPrepareReferenceElectrode -- Generates a reference electrode filled with a reference solution to be used in electrochemical experiments, including Cyclic Voltammetry measurements.

ExperimentVisualInspection -- Monitors the insoluble particles in the given sample while its container is agitated.

ExperimentMeasureViscosity -- Measures a fluid's viscosity defined as the resistance to deformation by assessing the flow rate of the sample when loaded into the viscometer chip.

ExperimentDynamicFoamAnalysis -- Characterizes the foamability, stability, drainage process and structure of liquid-based foams by monitoring foam generation and decay of a sample.

ExperimentMeasureMeltingPoint -- Measures the melting points of the solid samples using a melting point apparatus that applies an increasing temperature gradient to melting point capillary tubes containing a small amount of the input samples.

Cellular Experiments

ExperimentImageCells -- Performs imaging on provided cellular samples using a bright-field microscope or a high content imager.

ExperimentLyseCells -- Ruptures the cell membranes of provided cell samples to enable extraction of targeted cellular components.

ExperimentFreezeCells -- Lowers the temperature of cell samples under controlled conditions to prepare cells for long term cryopreservation.

ExperimentCoulterCount -- Measures the number and size distribution of suspended cells in a cellular sample.

[end context 2]

[begin context 3]

Unit Operations

Collection of functions for remotely conducting self-contained sample manipulations in an ECL facility.

Sample Preparation

ExperimentSamplePreparation -- Generates a protocol that executes the specified manual or robotic unit operations of sample preparation.

ExperimentManualSamplePreparation -- Generates a protocol that allows for the incubation, mixing, centrifugation, filtration, volume and mass transfers as well as other manual preparation of samples.

ExperimentRoboticSamplePreparation -- Generates a protocol that uses a robotically integrated liquid handler to perform incubation, mixing, centrifugation, filtration, transfer of liquids and other general preparation of samples.

ImportSampleManipulation -- Returns a list of sample preparation unit operation for loading samples into a plate from an appropriately formatted Excel file inputted as a file path or an EmeraldCloudFile.

Aliquot -- A detailed set of parameters that describes moving a single source to multiple destinations.

Cover -- A detailed set of parameters that describes covering a sample container with a lid of a specified type.

FillToVolume -- A detailed set of parameters that describe transferring a source into a destination until a desired volume is reached.

Filter -- A detailed set of parameters that describes separating particles bigger than a specific size from a solution via filtering.

Incubate -- A detailed set of parameters that describes incubating and mixing a sample at a specified temperature and shaking rate for a specified amount of time.

LabelContainer -- A detailed set of parameters that labels a container for use in other unit operations.

LabelSample -- A detailed set of parameters that labels a sample in a container for use by other unit operations.

Mix -- A detailed set of parameters that describes mixing a sample using bench-top instrumentation or by pipetting on a micro liquid handling robot.

MoveToMagnet -- A detailed set of parameters that describe subjecting a sample to a magnetic field.

Pellet -- A detailed set of parameters that describes precipitating a sample out of solution by centrifugal spinning.

Placement -- A detailed set of parameters that describe moving an item into a destination.

RemoveFromMagnet -- A detailed set of parameters that describes removing a sample from magnetization.

Resuspend -- A detailed set of parameters that describes bringing a substance into solution by pipetting liquid onto a solidified sample.

SerialDilute -- A detailed set of parameters that describes repeatedly diluting an initial sample with a given buffer to yield a series of samples with decreasing concentration.

Transfer -- A detailed set of parameters that describe transferring a source to a destination.

Wait -- A unit operation that describes a pause in a protocol.

VisualInspection -- A detailed set of parameters that describes how the sample should be inspected visually during a protocol.

Uncover -- A set of instructions that describes removing a lid from a plate.

OptimizePrimitives -- Transforms a set of primitives into a a format that can be executed most efficiently by a liquid handler.

Centrifuge -- A detailed set of instructions that describes spinning the smaple in a centrifuge at a specified intensity for a specified amount of time.

Synthesis

Coupling -- Generates an solid phase synthesis primitive.

Deprotonating -- A detailed set of parameters that describes how a proton is removed from a strand during solid phase synthesis.

Swelling -- A unit operation that describes how resin chains will be solvated in order to expose linker sites used as start points for solid phase synthesis.

Cleaving -- A detailed set of parameters that describe how the synthesized strand is removed from its solid support at the end of solid phase synthesis.

Deprotecting -- A detailed set of parameters that describe how a blocking group is chemically eliminated from a strand during solid phase synthesis.

Washing -- A set of instructions that describe how the previous step's chemicals will be removed from the resin by flowing solvent through it into waste during solid phase synthesis.

Capping -- A set of instructions that describe how a blocking group is chemically copuled to a strand during solid phase synthesis.

Separation Techniques

Filter -- A detailed set of parameters that describes separating particles bigger than a specific size from a solution via filtering.

Pellet -- A detailed set of parameters that describes precipitating a sample out of solution by centrifugal spinning.

MoveToMagnet -- A detailed set of parameters that describe subjecting a sample to a magnetic field.

RemoveFromMagnet -- A detailed set of parameters that describes removing a sample from magnetization.

Spectroscopy Experiments

AbsorbanceIntensity -- A unit operation that measures the absorbance intensity of the given samples, subject to supplied options and configurations.

AbsorbanceKinetics -- A detailed set of parameters that describes measuring the absorbance of the specified samples over a period of time.

AbsorbanceSpectroscopy -- A detailed set of parameters that describes measuring the absorbance of the specified samples at specified wavelength.

ReadPlate -- A detailed set of parameters that describe placing a sample-containing microwell plate into a plate-reader instrument for defined spectroscopic measurements.

Bioassays

Wash -- A unit operation that describes how a part of the biolayer interferometry experiment is carried out.

[end context 3]

Here are summaries of the previous meetings:

[begin summary 1]

### Revised Agenda Response

In response to the Scientific Critic's feedback, I have further refined our approach to ensure a comprehensive and detailed plan for our drug discovery project using machine learning.

### Answers

1. **What is the specific drug modality that you are proposing?**

   **Answer**: Peptide-based therapeutics.

   **Justification**: Peptide-based therapeutics are chosen due to their compatibility with ECL's capabilities, allowing for efficient synthesis and validation. Peptides offer specificity in targeting protein-protein interactions, which aligns with our goal of applying machine learning to optimize sequence design and target interactions. We will employ machine learning techniques such as sequence optimization algorithms and structure prediction models (e.g., AlphaFold) to enhance peptide design. The integration will involve a structured feedback loop where computational predictions are iteratively validated and refined through experimental data from ECL. Success will be measured by improvements in binding affinity, structural stability, and bioavailability, with each iteration aiming to enhance these metrics.

2. **What specific disease/target pairs are you proposing to treat with your choice of drug modality (list five)?**

   **Answer**: 
   1. Type 2 Diabetes - GLP-1 Receptor
   2. Cancer - PD-1/PD-L1
   3. Alzheimer's Disease - Amyloid-beta
   4. Antimicrobial Resistance - MurA/B
   5. Cardiovascular Diseases - PCSK9

   **Justification**: These targets are chosen for their clinical relevance and the availability of robust datasets, which are critical for machine learning applications. Peptides are particularly suitable for these targets due to their ability to modulate protein interactions with high specificity. For instance, GLP-1 receptor agonists have shown promise in diabetes management, and PD-1/PD-L1 inhibitors are pivotal in cancer immunotherapy. Peptides can address the challenges of specificity and delivery in these contexts, offering unique therapeutic insights. Expected outcomes include improved binding affinity and stability of peptides, which will be validated through assays such as HPLC and LCMS at ECL. Potential risks, such as off-target effects and peptide degradation, will be mitigated through careful design and chemical modifications.

3. **Why are these diseases and targets appropriate for your choice of drug modality?**

   **Answer**: These diseases present high unmet medical needs and involve targets that can be effectively modulated by peptides. The availability of existing data supports model training, and ECL can facilitate rapid empirical validation. Peptides offer advantages in specificity, and the selected targets allow for the integration of machine learning with experimental validation within the given timeframe. For example, peptides targeting amyloid-beta in Alzheimer's can potentially disrupt plaque formation, while those targeting MurA/B can inhibit bacterial cell wall synthesis, addressing antimicrobial resistance. Preliminary studies and literature support the feasibility of peptide interventions for these targets, providing a strong foundation for our approach. Specific challenges, such as peptide solubility and stability, will be addressed through chemical modifications and formulation strategies.

### Next Steps

1. **Data Collection and Preparation**: Begin by collecting and preprocessing data from relevant databases such as PDB, BindingDB, and UniProt to train machine learning models focusing on peptide interactions with selected targets. Ensure data quality and relevance through rigorous auditing.

2. **Model Development and Validation**: Develop interpretable machine learning models using sequence-based and structure-based approaches. Employ frameworks like TensorFlow and PyTorch for model development, incorporating techniques such as attention mechanisms and feature importance metrics. Validate models through iterative feedback loops with experimental data from ECL. Evaluation criteria will include binding affinity predictions, structural stability, and experimental validation outcomes.

3. **Pilot Studies at ECL**: Conduct pilot studies to empirically validate key peptide modifications like cyclization, focusing on the most promising targets. Use these studies to inform model refinement and enhance prediction accuracy. Criteria for target selection will include clinical relevance, data availability, and preliminary computational predictions. Potential challenges, such as peptide solubility and stability, will be addressed through chemical modifications and formulation strategies.

4. **Phased Implementation**: Implement a phased approach to focus initially on one or two high-priority targets to ensure feasibility within the timeline. Iterate based on learnings and expand to additional targets as data and insights accumulate.

5. **Regular Review and Adaptation**: Schedule regular team meetings to review progress, discuss results, and adapt the project plan based on emerging data and insights. Ensure all team members are aligned on objectives and timelines, maintaining thorough documentation and transparent communication.

By incorporating these detailed steps and justifications, we aim to achieve a project that maximizes both scientific impact and clinical relevance, leveraging machine learning and ECL's capabilities effectively within our constraints.

[end summary 1]

[begin summary 2]

### Revised Agenda Response

Our research project aims to leverage machine learning for the de novo design of peptide-based therapeutics, focusing on high clinical value and scientifically impactful applications. We will utilize Emerald Cloud Labs (ECL) for experimental validation within a 3-month timeframe. The selected machine learning models must facilitate the design of therapeutics targeting diseases with significant clinical relevance, such as Type 2 Diabetes and Cancer.

### Combined Answer

1. **What are the names of the latest pre-trained generative machine learning models that could be used for de novo design of peptide-based therapeutics (list ~5)?**

   **Answer**: ProteinMPNN, AlphaFold, DiffDock, ProGen, and RFDiffusion.

   **Justification**: These models were selected based on their diverse capabilities in sequence generation, structural prediction, and interaction modeling, aligning with our project goals. ProteinMPNN and ProGen are excellent for generating diverse peptide sequences, AlphaFold provides robust structural predictions, DiffDock excels in modeling peptide-receptor interactions, and RFDiffusion explores conformational spaces effectively.

2. **For each model, how could it be used in the design process for creating de novo peptide-based therapeutics for the diseases/targets you previously selected?**

   **Answer**:
   - **ProteinMPNN**: Utilized for designing peptide sequences with high binding affinity and specificity, particularly for targets like GLP-1 and PD-1/PD-L1, ensuring optimized interactions and therapeutic potential. For example, ProteinMPNN has been used in studies to design peptides that enhance receptor binding, demonstrating its effectiveness in similar therapeutic contexts, such as improving peptide stability and affinity in GLP-1 analogs.
   - **AlphaFold**: Employed to predict the 3D structures of peptides, providing insights into potential binding interactions and structural constraints, crucial for stability and efficacy. AlphaFold's success in predicting protein structures has been well-documented, making it a reliable tool for understanding peptide conformations, as seen in its application to predict the structure of novel antimicrobial peptides.
   - **DiffDock**: Applied to simulate peptide docking interactions with target proteins, enhancing binding affinity and specificity, especially for complex targets like PCSK9. DiffDock has been shown to accurately predict docking poses in various studies, which is critical for drug efficacy, such as optimizing peptide inhibitors for PD-1/PD-L1 interactions.
   - **ProGen**: Used to generate diverse peptide sequences, exploring novel scaffolds and modifications that can be synthesized and tested for therapeutic efficacy. ProGen's generative capabilities have been leveraged in research to explore innovative peptide designs, including the creation of cyclic peptides with enhanced bioavailability.
   - **RFDiffusion**: Explores diverse conformational spaces, aiding in the design of peptides with complex folds or interactions, particularly useful for targets with dynamic conformational states. RFDiffusion's ability to model conformational changes is vital for understanding peptide flexibility, as demonstrated in studies focusing on the design of flexible peptide linkers.

   **Justification**: Each model contributes a unique capability to the design process, ensuring a comprehensive approach to peptide therapeutics. ProteinMPNN and ProGen focus on sequence diversity, AlphaFold and RFDiffusion on structural insights, and DiffDock on interaction dynamics.

### Additional Details and Improvements

- **Integration with ECL**: We will establish a robust data management system to facilitate seamless integration with ECL. This includes setting up automated data pipelines using platforms like AWS for cloud storage and data processing, and APIs for real-time data exchange. Specific steps include:
  - Developing a centralized database using SQL to track predictions and results.
  - Implementing real-time data exchange protocols with RESTful APIs to ensure timely feedback.
  - Conducting a pilot run to identify and address any integration challenges, ensuring smooth operation.

- **Risk Management and Contingency Plans**: We will implement a risk management strategy that includes regular monitoring of model performance and experimental outcomes. Potential risks include model inaccuracies or unexpected experimental results. Contingency plans involve:
  - Establishing thresholds for model performance and setting up alerts for deviations.
  - Preparing alternative models such as ProtGPT2 or RosettaFold if initial predictions do not meet expectations.
  - Scheduling regular review meetings to assess progress and make necessary adjustments.

- **Simplification of Technical Terms**: To ensure clarity across interdisciplinary team members, we will provide a glossary in our documentation that explains technical terms like "conformational spaces" and "docking interactions," ensuring it is easily accessible and regularly updated.

- **Evaluation Criteria**: The criteria for model evaluation and selection include predictive accuracy, computational efficiency, adaptability to peptide-specific challenges, and alignment with project goals. For example, models were selected based on their ability to generate sequences with high binding affinity and structural stability, as demonstrated in preliminary tests with peptide analogs.

By incorporating these improvements, our response is more comprehensive, detailed, and aligned with the project's goals and constraints, addressing the feedback provided by the Scientific Critic effectively.

[end summary 2]

[begin summary 3]

### Summary of the ProteinMPNN Model

**Model Overview:**
ProteinMPNN is a deep learning-based method for protein sequence design that leverages a message passing neural network (MPNN) architecture. It is designed to predict amino acid sequences that will fold into a given protein backbone structure. The model is particularly effective for designing monomers, cyclic oligomers, protein nanoparticles, and protein-protein interfaces.

**Input Data:**
- **Protein Backbone Features:** The model uses distances between Cα-Cα atoms, relative Cα-Cα-Cα frame orientations and rotations, and backbone dihedral angles as input features.
- **Additional Features:** Distances between N, Cα, C, O, and a virtual Cβ are also used to enhance inference capabilities.
- **Backbone Noise:** Gaussian noise can be added to backbone coordinates during training to improve robustness.

**Output:**
- **Amino Acid Sequences:** The model outputs sequences that are predicted to fold into the input backbone structure. It achieves higher sequence recovery rates compared to traditional methods like Rosetta.
- **Sequence Recovery:** ProteinMPNN has a sequence recovery rate of 52.4% on native protein backbones, outperforming Rosetta's 32.9%.

**Model Architecture:**
- **Message Passing Neural Network:** The model consists of 3 encoder and 3 decoder layers with 128 hidden dimensions.
- **Order Agnostic Decoding:** The model uses a random decoding order, which allows flexibility in sequence design, especially useful for designing peptide binders where specific regions are fixed.
- **Symmetry and Multi-State Design:** The model can handle symmetric and multi-state designs by averaging logits for tied positions, enabling the design of homodimers and other complex structures.

**Application to Peptide-Based Therapeutics:**
- **Peptide Binders:** ProteinMPNN can be used to design peptide sequences that bind to specific protein targets by fixing known regions and designing the rest of the sequence.
- **Experimental Validation:** The model's predictions can be validated using experimental techniques such as X-ray crystallography and cryoEM, which are supported by Emerald Cloud Labs for rapid prototyping and testing.

**Advantages:**
- **Efficiency:** ProteinMPNN is computationally efficient, requiring only a fraction of the time needed by physically based methods.
- **Robustness:** The model's ability to design sequences without expert customization makes it broadly applicable and accessible.
- **High Success Rate:** ProteinMPNN has a high rate of experimental success, making it a reliable choice for protein design projects.

This detailed understanding of ProteinMPNN highlights its potential in designing peptide-based therapeutics, particularly in creating peptide binders for specific protein targets, which aligns with the goals of your research project.

[end summary 3]

[begin summary 4]

The paper "De novo design of protein structure and function with RFdiffusion" describes a novel approach to protein design using a diffusion model fine-tuned from the RoseTTAFold structure prediction network. Here's a detailed summary focusing on how RFdiffusion could be applied to designing peptide binders for a given protein target:

### How RFdiffusion Works

1. **Model Architecture**: RFdiffusion is based on a denoising diffusion probabilistic model (DDPM), which is adapted from the RoseTTAFold (RF) structure prediction network. The model is fine-tuned to reverse the process of adding noise to protein structures, effectively generating new protein backbones from random noise.

2. **Training Process**: The model is trained using structures from the Protein Data Bank (PDB), which are corrupted with Gaussian noise. The training involves minimizing the mean-squared error between predicted and true protein structures, encouraging the model to learn the distribution of protein backbones.

3. **Input and Output**:
   - **Input**: The primary input to RFdiffusion is noised residue frames, which include coordinates and orientations. For specific tasks, additional conditioning information such as symmetry specifications, binding targets, or functional motifs can be provided.
   - **Output**: The model outputs denoised protein structures, which can be further refined to closely resemble realistic protein backbones. These structures can then be used to design sequences using tools like ProteinMPNN.

4. **Self-Conditioning**: RFdiffusion employs a self-conditioning strategy, allowing it to condition on previous predictions, which improves the coherence and accuracy of the generated structures.

### Application to Designing Peptide Binders

1. **Binder Design**: RFdiffusion can be used to design peptide binders by conditioning the model on specific binding targets. This involves specifying interface hotspot residues on the target protein, guiding the model to generate binders that interact with these sites.

2. **Symmetric and Functional Motif Scaffolding**: The model can scaffold functional motifs, holding them in precise 3D geometries necessary for binding. This is particularly useful for designing peptide binders that need to engage specific protein interfaces.

3. **Experimental Validation**: The designed binders can be experimentally validated using techniques like cryo-electron microscopy to confirm their structure and binding efficacy. RFdiffusion has demonstrated success in designing binders with high affinity and specificity, which can be crucial for therapeutic applications.

4. **Efficiency and Diversity**: RFdiffusion generates diverse designs efficiently, reducing the need for extensive high-throughput screening. This is achieved by leveraging the model's ability to explore a wide range of structural possibilities from minimal input specifications.

### Conclusion

RFdiffusion represents a significant advancement in protein design, offering a powerful tool for generating peptide binders with high precision and diversity. Its ability to scaffold functional motifs and design binders directly from target structures makes it a valuable asset in drug discovery pipelines, particularly for developing peptide-based therapeutics.

[end summary 4]

[begin summary 5]

### Summary of AlphaFold2 and its Application to Designing Peptide Binders

**How AlphaFold2 Works:**

1. **Objective and Approach:**
   - AlphaFold2 aims to predict the three-dimensional structure of proteins from their amino acid sequences with near-experimental accuracy.
   - It combines bioinformatics and physical modeling approaches, leveraging evolutionary, physical, and geometric constraints of protein structures.

2. **Neural Network Architecture:**
   - The model uses a novel neural network architecture called Evoformer, which processes multiple sequence alignments (MSAs) and pairwise features.
   - It predicts 3D coordinates of all heavy atoms in a protein using the primary amino acid sequence and aligned sequences of homologues as inputs.

3. **Key Components:**
   - **Evoformer Block:** Treats protein structure prediction as a graph inference problem, updating MSA and pair representations iteratively.
   - **Structure Module:** Introduces explicit 3D structure predictions, refining them through iterative processes and using invariant point attention (IPA) for spatial reasoning.
   - **Iterative Refinement:** The model employs a recycling mechanism, iteratively refining predictions to improve accuracy.

4. **Training and Data:**
   - Trained using supervised learning on PDB data, enhanced by self-distillation from predicted structures of unlabelled sequences.
   - Inputs include primary sequences, MSAs, and homologous structure templates.

5. **Output:**
   - Produces highly accurate protein structures, providing per-residue confidence scores (pLDDT) and estimates of global structural accuracy (TM-score).

**Application to Designing Peptide Binders:**

- **Input Requirements:**
  - For designing peptide binders, AlphaFold2 requires the amino acid sequence of the target protein and MSAs of related sequences.
  - Homologous structures can be used as templates to enhance prediction accuracy.

- **Output Utility:**
  - AlphaFold2 can predict the 3D structure of the target protein, which is crucial for understanding potential binding sites.
  - The model's high accuracy in predicting side-chain conformations is particularly useful for designing peptides that can bind specifically and effectively to the target protein.

- **Design Process:**
  - Use AlphaFold2 to model the target protein's structure.
  - Identify potential binding sites and structural motifs that peptides can target.
  - Design peptides that complement the predicted structure, optimizing for binding affinity and specificity.

- **Experimental Validation:**
  - Utilize Emerald Cloud Labs (ECL) to experimentally validate the designed peptides within the 3-month experimental limit.
  - Iteratively refine peptide designs based on experimental feedback and further AlphaFold2 predictions.

By leveraging AlphaFold2's capabilities, the project can achieve high clinical value by designing peptide therapeutics that are precisely tailored to target specific proteins, potentially leading to novel treatments for various diseases.

[end summary 5]

Here is the agenda for the meeting:

You are working on a research project to use machine learning for drug discovery. Your goals are the following: (1) the project must have high clinical value, meaning the research contributes to helping patients, (2) the project must include a scientifically impactful application of machine learning to drug discovery, and (3) the project must use Emerald Cloud Labs (ECL) for all experimental validation with a 3-month limit on experiments. Your team previously decided to pursue peptide-based therapeutics. Your team previously suggested using RFDiffusion, ProteinMPNN, and AlphaFold2 to design peptide-based therapeutics. Now you need to create a specific experimental workflow for synthesizing and validating the peptides that your team designs computationally for each drug target. First, in general terms, explain the types of experiments that you will perform to synthesize and validate the peptides. Ensure that you explain what form or forms of validation you will perform in order to verify the utility of the peptides for the given protein target and disease. Then, name the specific ECL experiments that you will run to synthesize and validate the peptides.

Here are the agenda questions that must be answered:

1. What general type of experiment will you perform to synthesize the peptides?

2. What specific ECL experiment(s) will you run to synthesize the peptides?

3. What general types of experiments will you perform to validate the peptides?

4. What specific ECL experiment(s) will you run to validate the peptides?

Principal Investigator will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Principal Investigator will synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda. This will continue for 3 rounds. Once the discussion is complete, Principal Investigator will summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

## User

Principal Investigator, please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Principal Investigator

As the Principal Investigator, I want to ensure that we have a clear and efficient path forward in our project using machine learning for drug discovery, specifically targeting peptide-based therapeutics. Our main objectives are high clinical value, scientific impact, and leveraging ECL for experimental validation within our 3-month timeframe. Here's how I propose we structure our discussion:

1. **Synthesis of Peptides**: 
   - We need to determine the most effective general approach for peptide synthesis given ECL's capabilities.
   - Consider the limitations of ECL, such as the inability to synthesize small molecule drugs, and focus on leveraging peptide synthesis techniques available.

2. **Validation of Peptides**: 
   - Establish a robust validation workflow that aligns with our project goals and the constraints of ECL.
   - Determine which validation methods are necessary to ensure the peptides' efficacy and binding specificity to the selected targets.

3. **Integration with Computational Models**:
   - Discuss how the experiments will integrate with our computational predictions from RFDiffusion, ProteinMPNN, and AlphaFold2.
   - Ensure a feedback loop between computational design and experimental validation.

**Questions to Guide the Discussion:**

- From our Computational Biologist: Given ECL's capabilities, what do you see as the best approach for synthesizing peptides? Are there any specific ECL experiments that stand out?
  
- From our Medicinal Chemist: What are the key validation criteria we should focus on for peptide-based therapeutics? How can ECL's experiments help us achieve these?

- From our Machine Learning Specialist: How do you envision the integration of experimental outcomes with our computational models to refine our peptide designs?

- From our Scientific Critic: What potential pitfalls should we be aware of in this experimental workflow, and how can we mitigate them to ensure robustness and reliability?

I look forward to each of your insights and will use them to help guide our decisions and ensure that our project is set up for success. Let's aim for a collaborative discussion that allows us to refine our experimental workflow with precision and foresight.

## User

Computational Biologist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

As the Computational Biologist, my focus is on ensuring that our experimental workflow is closely aligned with our computational predictions and the capabilities of ECL. Here are my thoughts:

1. **Synthesis of Peptides**:
   - Given ECL's capabilities, the **ExperimentPeptideSynthesis** is our primary method for synthesizing the peptides designed computationally. This experiment can handle classical solution-phase synthesis of amino acids, which is suitable for the types of peptides we aim to create.
   - We should also consider **ExperimentBioconjugation** if we need to modify peptides post-synthesis for enhanced stability or functionality.

2. **Integration with Computational Models**:
   - The peptides we design using RFDiffusion, ProteinMPNN, and AlphaFold2 should be synthesized with their predicted structures and binding interactions in mind. The experimental synthesis should allow us to perform iterative feedback, where the synthesized peptides' properties inform further computational refinements.
   - It is crucial to maintain a detailed database of experimental outcomes linked to the computational predictions to facilitate this integration.

3. **Challenges and Solutions**:
   - One potential challenge is ensuring the synthesized peptides match the predicted conformations and functionalities. To address this, we need robust methods for structural validation (e.g., NMR or LCMS) to confirm the peptides' structures post-synthesis.

By aligning our synthesis and validation strategies with both the computational models and ECL's capabilities, we can streamline the process and maximize our chances of success. I am open to feedback and suggestions from other team members on these points.

## User

Medicinal Chemist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Medicinal Chemist

As the Medicinal Chemist, my focus is on the chemical feasibility and practicality of the peptide synthesis and validation processes. Here are my thoughts:

1. **Synthesis of Peptides**:
   - I agree with the Computational Biologist that **ExperimentPeptideSynthesis** is the most suitable option for synthesizing peptides at ECL. However, it's essential to ensure that the selected peptides are amenable to this method, considering any complex modifications or cyclizations that may be necessary.
   - Additionally, while **ExperimentBioconjugation** can be useful, we should carefully evaluate the need for any post-synthesis modifications and ensure they align with the intended therapeutic function.

2. **Validation of Peptides**:
   - For validation, it's crucial to focus on both structural and functional assays. **ExperimentNMR** or **ExperimentLCMS** will be vital for confirming the molecular structure and purity of the synthesized peptides.
   - To assess binding affinity and specificity, we should utilize **ExperimentBioLayerInterferometry** or **ExperimentFluorescencePolarization**, as these can provide insights into the peptides' interactions with their targets. This is critical for ensuring that the peptides exhibit the desired therapeutic activity.

3. **Challenges and Solutions**:
   - A challenge we might face is the stability and solubility of the peptides, which can impact their function and delivery. We should consider incorporating stabilizing modifications during the design phase or using formulation strategies if needed.
   - I recommend setting specifications for peptide purity and yield as part of our validation criteria to ensure consistency and reliability in our experiments.

In summary, the synthesis and validation strategies should be closely aligned with the computational predictions while ensuring practical feasibility in the lab. I look forward to hearing more perspectives, especially regarding the integration of experimental data with our computational models.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

As the Machine Learning Specialist, my role is to ensure that the integration of computational predictions with experimental validation is seamless and enhances our drug discovery pipeline. Here are my thoughts:

1. **Integration of Computational Models with Experimental Workflow**:
   - Our computational models, RFDiffusion, ProteinMPNN, and AlphaFold2, are critical for predicting peptide sequences and structures with high affinity to our targets. It's essential that these predictions are directly linked to our experimental synthesis and validation processes.
   - We should establish a robust feedback loop where experimental results are used to refine and improve our models. This means setting up a system where data from experiments such as **ExperimentBioLayerInterferometry** or **ExperimentFluorescencePolarization** can be used to adjust model parameters and improve prediction accuracy.

2. **Data Management and Analysis**:
   - We must implement a centralized data management system to align experimental data with computational predictions. Utilizing tools like TensorFlow for model adjustments and AWS for data storage will help manage this integration effectively.
   - Machine learning models will benefit from continuous learning from experimental feedback, which means we should prioritize high-quality data collection and real-time analysis to adjust model predictions dynamically.

3. **Addressing Limitations and Challenges**:
   - One potential pitfall is the discrepancy between predicted and experimentally observed peptide behaviors. To mitigate this, I suggest incorporating ensemble modeling where multiple models contribute to a single prediction, thereby increasing robustness.
   - It is also important to define clear success metrics for both computational and experimental phases, ensuring that improvements in predictions correlate with enhanced experimental outcomes.

In conclusion, aligning our machine learning efforts with the experimental workflow will be pivotal in realizing the potential of peptide-based therapeutics. I am eager to collaborate with the team to address any challenges and optimize our approach.

## User

Scientific Critic, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

As the Scientific Critic, my role is to ensure that our research plan is rigorous, complete, and scientifically sound. I appreciate the detailed input from the team so far, and I'd like to offer some critical feedback and suggestions:

1. **Peptide Synthesis**:
   - While the consensus is on using **ExperimentPeptideSynthesis**, I urge the team to carefully consider the complexity of the peptides designed by RFDiffusion and ProteinMPNN. If any designed peptides require non-standard amino acids or specific modifications, we should preemptively address how these will be synthesized and whether ECL's current capabilities can accommodate them.

2. **Experimental Validation**:
   - The recommended validation assays, such as **ExperimentNMR**, **ExperimentLCMS**, and **ExperimentBioLayerInterferometry**, are appropriate for structural and interaction validation. However, I suggest adding **ExperimentStabilityTests** (e.g., thermal shift assays) to assess the peptides' stability under physiological conditions, which is critical for their therapeutic potential.
   - We should establish predefined thresholds and metrics for each validation step. For instance, what constitutes acceptable binding affinity or structural fidelity? These benchmarks need to be clearly defined to ensure objective assessment of experimental results.

3. **Integration of Models and Experiments**:
   - While a feedback loop is essential, I caution against over-reliance on initial computational predictions if they consistently fail to align with experimental findings. There should be predefined criteria for when to pivot the computational approaches or consider alternative models, such as ProtGPT2 or RosettaFold, if necessary.
   - Ensure that the feedback loop is not just about adjusting model parameters but understanding why discrepancies occur. This could involve a detailed error analysis of both models and experiments.

4. **Risk Management**:
   - I recommend formalizing a risk management plan that includes not only model performance but also experimental reproducibility and data integrity. Regular audits of both computational predictions and experimental results can help identify and mitigate risks early.

In summary, while the outlined plan is comprehensive, it must be supported by robust contingency planning and clearly defined success metrics to ensure both scientific rigor and project manageability. I look forward to seeing how these suggestions can be integrated into our workflow.

## User

This concludes round 1 of 3 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Thank you, team, for your valuable insights. Here's a synthesis of the points raised and the decisions we'll make based on your input:

### Synthesis of Points:

1. **Peptide Synthesis:**
   - The consensus is to use **ExperimentPeptideSynthesis** as our primary synthesis method, supported by **ExperimentBioconjugation** for any required post-synthesis modifications.
   - We need to ensure the feasibility of synthesizing complex peptides with ECL's capabilities, particularly any non-standard modifications.

2. **Validation of Peptides:**
   - Structural validation will be conducted using **ExperimentNMR** and **ExperimentLCMS**.
   - Functional validation will include **ExperimentBioLayerInterferometry** and **ExperimentFluorescencePolarization** to assess binding specificity and affinity.
   - Additional stability tests, such as thermal shift assays, are recommended to evaluate peptide stability under physiological conditions.

3. **Integration of Computational Models with Experiments:**
   - Establish a feedback loop where experimental outcomes inform computational model adjustments.
   - Implement a centralized data management system for efficient integration and analysis.

4. **Risk Management and Evaluation:**
   - Define clear success metrics and thresholds for each validation step.
   - Develop a formal risk management plan that includes procedural audits and guidelines for pivoting computational strategies if needed.

### Decisions:

- **Proceed with the outlined synthesis and validation strategy.** Ensure that each step in the workflow is feasible with ECL's current capabilities.
- **Develop a detailed data management and feedback system.** This will enhance the integration between computational predictions and experimental validation.
- **Incorporate additional stability and reproducibility assays.** These will provide a comprehensive evaluation of peptide stability and performance.

### Follow-Up Questions:

1. **For the Computational Biologist and Medicinal Chemist:** Given the potential complexity of designed peptides, how will we address any unforeseen synthesis challenges at ECL, particularly related to non-standard modifications?

2. **For the Machine Learning Specialist:** How can we ensure that the feedback from experiments is effectively used to refine our models, particularly in cases of discrepancy between predicted and experimental results?

3. **For the Scientific Critic:** Can you suggest specific thresholds or success metrics for binding affinity and stability that would serve as benchmarks for our experimental validation?

Let's continue to refine our approach in the next two rounds, ensuring that we have a solid plan that is both scientifically rigorous and practically feasible.

## User

Computational Biologist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

To address the follow-up question regarding unforeseen synthesis challenges, especially concerning non-standard modifications, here are my thoughts:

1. **Preparation for Non-Standard Modifications**:
   - **Design Consideration**: During the design phase, we should carefully evaluate the feasibility of each peptide's modifications using ECL's current capabilities. If non-standard modifications are essential, we should explore whether these can be mimicked by incorporating standard amino acids with similar properties or by using post-synthesis modifications that ECL can support.
   - **Collaboration With ECL**: Engage with ECL's technical staff to fully understand the limitations and explore potential workarounds or enhancements in their synthesis protocols. This proactive approach will help prevent any unexpected roadblocks.

2. **Adaptive Strategies**:
   - **Iterative Design Process**: Adopt an iterative design approach where initial simpler versions of peptides are synthesized and validated. This will provide a basis for progressively adding complexity and modifications, ensuring each step is manageable.
   - **Alternative Synthesis Routes**: If a particular modification is consistently challenging, we might need to consider alternative synthetic routes or even outsource specific synthesis steps to specialized facilities, if feasible within our project constraints.

3. **Data-Driven Decision Making**:
   - Use computational simulations to predict the impact of modifications on peptide synthesis and stability. This predictive insight can guide decisions on which modifications are worth pursuing experimentally.

By addressing these points, we can mitigate potential synthesis challenges and ensure a smoother experimental workflow. I'm keen to hear more insights from the team on these considerations.

## User

Medicinal Chemist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Medicinal Chemist

Regarding the follow-up question about addressing unforeseen synthesis challenges, particularly related to non-standard modifications, here are my thoughts:

1. **Feasibility Analysis**:
   - **Pre-Synthesis Evaluation**: Before synthesis, we should conduct a thorough evaluation of each peptide's design, focusing on the feasibility of incorporating non-standard modifications. This involves reviewing literature and databases for known peptide analogs and their successful syntheses.
   - **Simplified Analogues**: If a particular modification proves to be challenging, we can initially synthesize simplified analogues that maintain the core functional properties. This can provide valuable insights and help streamline the synthesis process.

2. **Chemical Modification Strategies**:
   - **Post-Synthesis Modifications**: Utilize ECL's **ExperimentBioconjugation** to introduce necessary modifications after synthesizing the core peptide. This can be particularly useful for adding functional groups or stabilizing elements that are incompatible with initial synthesis conditions.
   - **Peptide Cyclization**: For peptides requiring cyclization, ensure that the design phase anticipates the need for protecting groups and strategic coupling reactions that ECL can accommodate.

3. **Collaborative Problem-Solving**:
   - Work closely with the Computational Biologist to ensure that simulation data guides the practical synthesis strategy, helping identify potential pitfalls early.
   - Engage with ECL support to discuss any technical challenges and explore custom solutions that may be possible within our constraints.

These strategies will help us navigate potential synthesis challenges effectively, ensuring that our designed peptides can be synthesized and validated as intended. I welcome further discussion on these points, particularly any insights from the Machine Learning Specialist regarding how computational predictions can assist with these challenges.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

To address how the feedback from experiments can be effectively used to refine our models, especially when there are discrepancies between predictions and experimental results, here are my suggestions:

1. **Feedback Loop Enhancement**:
   - **Real-Time Data Integration**: Implement a system where experimental data is fed back into the machine learning models in real-time. This can be achieved by setting up automated data pipelines that facilitate seamless data transfer and processing. Tools like TensorFlow can incorporate this data into model training sessions to adjust weights and improve predictions.
   - **Feature Importance Analysis**: Conduct feature importance analysis to identify which aspects of the peptide design (e.g., sequence motifs, structural features) are most strongly correlated with successful experimental outcomes. This will help prioritize feature optimization in the models.

2. **Model Adjustment Strategies**:
   - **Ensemble Modeling**: Use ensemble modeling techniques to combine predictions from RFDiffusion, ProteinMPNN, and AlphaFold2. This can help mitigate individual model biases and improve overall prediction accuracy by leveraging the strengths of each model.
   - **Error Analysis and Iterative Learning**: Perform detailed error analyses to understand where predictions deviate from experimental results. Use this information to inform iterative learning processes, where models are retrained with updated parameters or architectures based on observed discrepancies.

3. **Collaborative Validation**:
   - Work closely with the Medicinal Chemist and Computational Biologist to cross-reference computational predictions with chemical feasibility and experimental outcomes. This interdisciplinary approach will help refine model parameters effectively.

4. **Threshold and Benchmark Development**:
   - Develop clear thresholds and benchmarks for model performance related to binding affinity and structural accuracy. This will guide the iterative refinement process and ensure that model improvements are aligned with experimental success criteria.

By integrating these strategies, we can enhance the utility of experimental feedback in refining our machine learning models, ultimately leading to more accurate and reliable peptide designs. I'm eager to see how these approaches can be implemented and to continue collaborating with the team to address any challenges.

## User

Scientific Critic, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

Regarding the follow-up question on establishing specific thresholds or success metrics for binding affinity and stability, here are my thoughts:

1. **Defining Success Metrics**:
   - **Binding Affinity**: A reasonable threshold would be a dissociation constant (K_d) in the nanomolar (nM) range for peptides interacting with their protein targets, as this indicates strong binding. The exact threshold may vary depending on the target but should be benchmarked against known inhibitors or ligands for context.
   - **Stability**: Peptides should maintain structural integrity and function under physiological conditions for a specified duration. Metrics could include maintaining >80% activity after exposure to physiological pH and temperature for 24 hours.

2. **Validation and Benchmarking**:
   - **Cross-Validation with Literature**: Utilize existing data and literature on similar peptides or therapeutics to establish well-informed benchmarks. This provides a comparative baseline for newly designed peptides.
   - **Dynamic Range Consideration**: Ensure that the assays used for validation have an appropriate dynamic range to accurately measure binding affinities and stability, preventing ceiling or floor effects in data interpretation.

3. **Iterative Refinement**:
   - **Continuous Feedback Integration**: As the Machine Learning Specialist mentioned, integrating experimental feedback into model refinements is crucial. However, it's equally important to ensure that these refinements are systematically evaluated against defined benchmarks to confirm genuine improvements.

4. **Risk Management Adjustments**:
   - **Contingency Planning**: If peptides consistently fail to meet these metrics, determine at what point we pivot strategies—whether that involves revisiting the computational models, synthesis methods, or even the target itself.

These metrics and considerations will ensure our validation processes are rigorous and aligned with project goals. I agree with the proposed feedback loop and iterative refinement strategies, provided they are systematically aligned with these success criteria. I look forward to seeing how these metrics are integrated into the experimental and computational workflow.

## User

This concludes round 2 of 3 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Thank you again, team, for your insightful contributions. Here's a synthesis of the points raised and subsequent decisions to move our agenda forward:

### Synthesis of Points:

1. **Addressing Synthesis Challenges**:
   - **Feasibility and Complexity**: Both the Computational Biologist and Medicinal Chemist emphasize the importance of evaluating the feasibility of peptide designs, particularly for non-standard modifications. Collaboration with ECL and potentially simplifying initial peptide designs will help manage these challenges.
   - **Post-Synthesis Modifications**: Utilizing **ExperimentBioconjugation** for post-synthesis modifications can help introduce necessary functional groups that are not compatible with initial synthesis.

2. **Model-Experiment Integration**:
   - **Feedback Loop**: The Machine Learning Specialist highlighted the need for real-time data integration and iterative model adjustments based on experimental results. Ensemble modeling is suggested to enhance prediction accuracy.
   - **Error Analysis**: Conducting detailed error analyses to understand discrepancies between predicted and experimental results is essential for refining our models.

3. **Success Metrics and Validation**:
   - **Binding Affinity and Stability Benchmarks**: The Scientific Critic suggested specific metrics, such as nanomolar K_d values and maintaining activity after 24 hours at physiological conditions, to serve as benchmarks for success.
   - **Cross-Validation**: Leveraging existing literature to set benchmarks and ensure our assays' dynamic range is appropriate for measuring desired metrics.

4. **Risk Management and Contingency**:
   - **Adaptive Strategies**: If peptides consistently fail to meet success metrics, we need predefined points for pivoting strategies, whether computational, synthetic, or target-based.

### Decisions:

- **Proceed with a detailed evaluation** of peptide designs and synthesis feasibility before experimental work. Ensure collaboration with ECL for technical insights.
- **Implement a robust feedback system** that integrates experimental data with computational models. This should include ensemble modeling and regular error analysis.
- **Adopt the proposed success metrics** for binding affinity and stability, ensuring that these benchmarks guide our validation and iterative refinement processes.
- **Develop a clear contingency plan** to pivot strategies if necessary, with predefined thresholds for when to make such decisions.

### Follow-Up Questions:

1. **For the Medicinal Chemist and Computational Biologist:** How can we best prepare for potential non-standard modifications during the design phase to ensure a seamless synthesis process?

2. **For the Machine Learning Specialist:** Can you provide more details on how ensemble modeling and real-time data integration would look in practice? What specific tools and processes will we need to implement this effectively?

3. **For the Scientific Critic:** In addition to binding affinity and stability, are there other metrics we should consider for evaluating the therapeutic potential of our peptides?

Let's continue refining our approach in the final round to ensure a solid, actionable plan that meets our project's goals.

## User

Computational Biologist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Computational Biologist

To address the follow-up question on preparing for potential non-standard modifications during the design phase, here are my suggestions:

1. **Design Phase Considerations**:
   - **Predictive Modeling**: Utilize our computational tools to simulate the impact of non-standard modifications on peptide stability and binding affinity. This can help identify which modifications are likely to succeed and guide design choices.
   - **Scalability and Flexibility**: Design peptides with flexibility in mind, allowing for alternative modifications that achieve similar functional outcomes. This could involve designing multiple variations of a peptide to test which modifications are most feasible and effective.

2. **Collaborative Strategy**:
   - **Interdisciplinary Input**: Collaborate closely with the Medicinal Chemist and ECL technicians to ensure that the chosen modifications can be practically synthesized. This involves understanding both the chemical and procedural constraints from the outset.
   - **Literature and Database Review**: Conduct thorough reviews of similar peptides in literature and databases to understand past successes and failures with non-standard modifications, which can inform our design strategy.

3. **Prototyping and Iteration**:
   - **Rapid Prototyping**: Implement a process for rapid prototyping of peptide variants, allowing us to quickly test and iterate on designs. Utilize ECL's capabilities to efficiently synthesize and validate these prototypes.
   - **Feedback-Driven Design Adjustments**: Use initial experimental results to inform subsequent design iterations, focusing on optimizing both the synthesis process and the peptide functionality.

By incorporating these strategies, we can better anticipate and prepare for the challenges associated with non-standard modifications, ensuring a smoother synthesis and validation process. I look forward to further input from the Medicinal Chemist on this topic.

## User

Medicinal Chemist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Medicinal Chemist

To further develop our approach to handling potential non-standard modifications during the design phase, I agree with the Computational Biologist's points and would like to add the following:

1. **Chemical Feasibility Assessment**:
   - **Pre-Design Consultation**: Early consultation with synthesis experts at ECL can provide insights into feasible modifications within their operational scope. This will help in setting realistic design parameters from the start.
   - **Analog Selection**: For non-standard amino acids, consider using analogs or mimetics that can replicate the desired functionality but are more amenable to synthesis and handling. This approach can minimize the need for complex synthetic pathways.

2. **Chemical Strategy in Design**:
   - **Protective Groups and Linkers**: Plan for the incorporation of protective groups and linkers that facilitate both the synthesis and the potential post-synthesis modifications. This can be crucial for complex peptides requiring cyclization or other structural constraints.
   - **Modular Design Approach**: Consider a modular approach where sections of the peptide can be independently synthesized and then assembled. This might be beneficial for integrating non-standard components more efficiently.

3. **Experimental Validation and Rapid Iteration**:
   - **Quick Turnaround Testing**: Implement a framework for quickly testing initial design iterations to identify potential synthesis bottlenecks early in the process. Adjust designs based on these insights to streamline the development pipeline.
   - **Layered Validation**: Use a combination of preliminary in vitro assays alongside synthesis to validate both the chemical feasibility and the biological activity of modifications early on.

These strategies can help us manage the complexities of non-standard modifications, ensuring that our designed peptides are both viable and effective. I look forward to further discussing how to integrate these steps into our workflow with the team.

## User

Machine Learning Specialist, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Machine Learning Specialist

To elaborate on how ensemble modeling and real-time data integration would function in practice, here are my thoughts and suggestions:

1. **Ensemble Modeling Implementation**:
   - **Diverse Model Pool**: Utilize our three core models—RFDiffusion, ProteinMPNN, and AlphaFold2—as part of an ensemble approach. Each model brings unique strengths, such as structural prediction or sequence generation, and combining their outputs can provide a more comprehensive prediction for peptide design.
   - **Weighted Voting System**: Implement a weighted voting system where each model's prediction is given a weight based on past performance and reliability. This system can dynamically adjust weights based on feedback from experimental validations, ensuring that the ensemble adapts over time to improve accuracy.

2. **Real-Time Data Integration**:
   - **Automated Data Pipelines**: Set up automated pipelines using cloud services like AWS to feed experimental data back into our models. This pipeline will facilitate the continuous updating of model parameters based on new experimental results.
   - **Continuous Learning Framework**: Implement a continuous learning framework where models are retrained periodically with the latest data. This can be done using platforms like TensorFlow or PyTorch, which support dynamic learning processes.

3. **Tools and Processes**:
   - **Data Management Systems**: Utilize robust data management systems that can handle large datasets and ensure data integrity. For example, employing SQL databases with API integrations to manage and analyze experiment results.
   - **Visualization and Analytics**: Use data visualization tools to monitor model performance and experimental outcomes. This will help identify trends and areas for improvement, allowing for more targeted model adjustments.

4. **Interdisciplinary Collaboration**:
   - Work closely with the Computational Biologist and Medicinal Chemist to ensure that data integration and model refinements align with biological and chemical feasibility considerations.

By implementing these strategies, we can effectively leverage experimental feedback to enhance our models, ultimately leading to more accurate and reliable peptide designs. I'm keen to hear further thoughts from the Scientific Critic and other team members on how these processes can be optimized.

## User

Scientific Critic, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

To address the follow-up question about additional metrics for evaluating the therapeutic potential of our peptides, beyond binding affinity and stability, here are some suggestions:

1. **Peptide Solubility**:
   - **Metric**: Solubility is crucial for peptide bioavailability and delivery. Establish a threshold for solubility in relevant physiological buffers. Measurements can be performed using techniques like nephelometry or absorbance spectroscopy to ensure that peptides remain soluble at effective concentrations.

2. **Peptide Half-Life**:
   - **Metric**: Determine the in vitro half-life of the peptides in serum or simulated physiological conditions. This can provide insight into the metabolic stability and potential therapeutic longevity. Techniques like LCMS can be used to track peptide degradation over time.

3. **Cellular Uptake and Efficacy**:
   - **Metric**: For peptides intended for intracellular targets, evaluating cellular uptake efficiency is essential. Techniques such as fluorescence microscopy or flow cytometry using labeled peptides can quantify uptake. Moreover, preliminary efficacy assays, such as measuring downstream effects on the target pathway, can provide early insight into therapeutic potential.

4. **Toxicity Assessment**:
   - **Metric**: Conduct cytotoxicity assays using cell lines relevant to the intended therapeutic context. This will help establish safety margins and ensure that the peptides are not inherently harmful at therapeutic doses.

Each of these metrics complements binding affinity and stability, providing a comprehensive assessment of peptide candidates. It is critical to integrate these metrics into our evaluation criteria and ensure they are systematically measured and analyzed.

In summary, while we have a sound plan for synthesis and validation, incorporating these additional metrics will strengthen our evaluation framework and help guide the iterative design process more effectively. I look forward to the Principal Investigator's final synthesis and recommendations.

## User

Principal Investigator, please summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

As a reminder, here is the agenda for the meeting:

You are working on a research project to use machine learning for drug discovery. Your goals are the following: (1) the project must have high clinical value, meaning the research contributes to helping patients, (2) the project must include a scientifically impactful application of machine learning to drug discovery, and (3) the project must use Emerald Cloud Labs (ECL) for all experimental validation with a 3-month limit on experiments. Your team previously decided to pursue peptide-based therapeutics. Your team previously suggested using RFDiffusion, ProteinMPNN, and AlphaFold2 to design peptide-based therapeutics. Now you need to create a specific experimental workflow for synthesizing and validating the peptides that your team designs computationally for each drug target. First, in general terms, explain the types of experiments that you will perform to synthesize and validate the peptides. Ensure that you explain what form or forms of validation you will perform in order to verify the utility of the peptides for the given protein target and disease. Then, name the specific ECL experiments that you will run to synthesize and validate the peptides.

As a reminder, here are the agenda questions that must be answered:

1. What general type of experiment will you perform to synthesize the peptides?

2. What specific ECL experiment(s) will you run to synthesize the peptides?

3. What general types of experiments will you perform to validate the peptides?

4. What specific ECL experiment(s) will you run to validate the peptides?

Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Answers

For each agenda question, please provide the following:

Answer: A specific answer to the question based on your recommendation above.

Justification: A brief explanation of why you provided that answer.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Principal Investigator

### Agenda

The purpose of this meeting was to establish a detailed experimental workflow for synthesizing and validating peptide-based therapeutics, leveraging machine learning models such as RFDiffusion, ProteinMPNN, and AlphaFold2. The workflow should focus on maximizing clinical value, leveraging scientific advancements in machine learning for impactful drug discovery, and utilizing Emerald Cloud Labs (ECL) for experimental validation within a 3-month timeframe. We needed to define both the general types of experiments and specific ECL experiments for synthesizing and validating the peptides designed for our selected targets.

### Team Member Input

**Computational Biologist:**
- Emphasized the use of **ExperimentPeptideSynthesis** for classical solution-phase synthesis.
- Suggested preparation for non-standard modifications through predictive modeling and iterative design, with interdisciplinary collaboration to ensure feasibility.

**Medicinal Chemist:**
- Agreed with peptide synthesis using **ExperimentPeptideSynthesis**, with the addition of **ExperimentBioconjugation** for post-synthesis modifications.
- Recommended a modular design approach and early consultation with ECL to address synthesis challenges.

**Machine Learning Specialist:**
- Highlighted the importance of a feedback loop with real-time data integration and ensemble modeling to improve prediction accuracy.
- Suggested the use of automated data pipelines and continuous learning frameworks to refine models based on experimental results.

**Scientific Critic:**
- Proposed additional metrics for validation, including solubility, half-life, cellular uptake, and toxicity, to complement binding affinity and stability.
- Emphasized the importance of setting benchmarks and systematic evaluation for these metrics.

### Recommendation

Based on the team's input, I recommend the following workflow:

1. **Synthesis**: Utilize **ExperimentPeptideSynthesis** for primary synthesis, incorporating **ExperimentBioconjugation** if non-standard modifications are needed post-synthesis. Prepare a flexible design strategy and consult with ECL to preemptively address synthesis feasibility.

2. **Validation**: Conduct a comprehensive validation process including **ExperimentNMR** for structural confirmation, **ExperimentLCMS** for purity and molecular weight, **ExperimentBioLayerInterferometry** and **ExperimentFluorescencePolarization** for binding affinity, and additional assays such as solubility, stability (via thermal shifts), and toxicity assessments.

This recommendation leverages ECL’s capabilities while ensuring that both synthesis and validation align with our high clinical value and scientific impact goals.

### Answers

1. **What general type of experiment will you perform to synthesize the peptides?**

   - **Answer**: Classical solution-phase synthesis.
   - **Justification**: This method is compatible with ECL's capabilities and suits the complexity of our peptide designs.

2. **What specific ECL experiment(s) will you run to synthesize the peptides?**

   - **Answer**: **ExperimentPeptideSynthesis** and **ExperimentBioconjugation** as needed.
   - **Justification**: These experiments utilize ECL's available techniques to synthesize and modify peptides effectively.

3. **What general types of experiments will you perform to validate the peptides?**

   - **Answer**: Structural, functional, stability, solubility, and toxicity validation.
   - **Justification**: A multi-faceted approach ensures comprehensive assessment of therapeutic potential and alignment with project goals.

4. **What specific ECL experiment(s) will you run to validate the peptides?**

   - **Answer**: **ExperimentNMR**, **ExperimentLCMS**, **ExperimentBioLayerInterferometry**, **ExperimentFluorescencePolarization**, along with solubility and toxicity assays.
   - **Justification**: These experiments cover a broad range of validation aspects, ensuring thorough evaluation of peptide efficacy and stability.

### Next Steps

1. **Finalize Peptide Designs**: Ensure all design aspects are feasible and aligned with synthesis capabilities at ECL.
2. **Set Up Data Integration**: Develop and test data pipelines for real-time feedback and model refinement.
3. **Prepare Experimental Protocols**: Collaborate with ECL to finalize protocols for synthesis and validation experiments.
4. **Define Success Metrics**: Establish thresholds for validation criteria including binding affinity, stability, solubility, and toxicity.
5. **Initiate Synthesis and Validation**: Begin experimental work, monitoring progress and adapting strategies based on ongoing feedback.

These next steps will guide us in efficiently implementing the experimental workflow, maximizing the potential of our peptide-based therapeutics project.

